AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

DIACEUTICS PLC

Director's Dealing Jun 6, 2023

7596_dirs_2023-06-06_d774f3d5-2521-45c3-a121-f388b566e7ae.html

Director's Dealing

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

RNS Number : 7228B

Diaceutics PLC

06 June 2023

6 June 2023

Diaceutics PLC

("Diaceutics" or "the Company")

Purchase and Sale of Shares and PDMR Shareholdings

Diaceutics PLC, (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry announces the following Director and PDMR share dealing.

On 5 June 2023, Nick Roberts, CFO of Diaceutics, purchased 21,742 ordinary shares of £0.002 each in the Company ("Ordinary Shares") at a price of 91.75 pence per Ordinary Share. As a result of the purchase, Nick's shareholding is 62,576 Ordinary Shares, representing approximately 0.07% of the Company's issued share capital.

Enquiries:

Diaceutics PLC
Peter Keeling, Chief Executive Officer

Nick Roberts, Chief Financial Officer
Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600
Ben Maddison
Nick Harland

Nick Adams

Kate Hanshaw
Alma PR Tel: +44(0)20 3405 0205
Caroline Forde [email protected]
Kieran Breheny

Matthew Young

Kinvara Verdon

About Diaceutics

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.

DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person closely associated
a. Name Nick Roberts
2 Reason for notification
a. Position/Status CFO
b. Initial notification/

Amendment
Initial
3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
b. LEI 213800VEWQBB39ZB8J81
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a. Description of the financial instrument, type of instrument



Identification Code
Ordinary shares of £0.002 each

ISIN:  GB00BJQTGV64
b. Nature of the transaction Purchase
c. Price(s) and volume(s) Share purchase:
Price(s) Volume(s)
91.75p 21,742
d. Date of the transaction 5 June 2023
e. Place of the transaction AIM Market of the London Stock Exchange

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFFFLIRRIEIIV

Talk to a Data Expert

Have a question? We'll get back to you promptly.